Clinical trials: Tamoxifen
Osteoporosis, Postmenopausal
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
- Trial name
- MORE (NCT00670319)
- Testing
- Raloxifene HCL
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 7,705 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases, Breast Neoplasms
Raloxifene Use for The Heart
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
- Trial name
- NCT00190593
- Testing
- raloxifene
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer.
- Trial name
- OVELIA (NCT04906395)
- Testing
- TOL2506, Tamoxifen, Letrozole Tablets
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 555 sites in United States, Argentina and 26 more
- Volunteers
- 4,556 people
- Sponsor
- Stemline Therapeutics, Inc.
Locally Advanced or Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human…
- Trial name
- NCT05296798
- Testing
- Phesgo, Giredestrant, Docetaxel
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 922 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years) This Pfizer sponsored trial is part…
- Trial name
- TEAM (NCT00279448)
- Testing
- exemestane, tamoxifen
- Where
- 59 sites in France
- Volunteers
- 9,779 people
- Sponsor
- Pfizer
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers
- Trial name
- NCT03764462
- Testing
- AD-101 45mg, Raloxifene 60mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but…
- Trial name
- NCT06440967
- Testing
- Fezolinetant, Tamoxifen, Aromatase inhibitor
- Where
- 110 sites in Canada, Czechia and 9 more
- Volunteers
- 982 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pharmacokinetics
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects.
- Trial name
- NCT01189500
- Testing
- Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoporosis, Postmenopausal
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal…
- Trial name
- NCT00790101
- Testing
- Risedronate, Raloxifene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Breast Neoplasms
Study of Docetaxel in Breast Cancer Patients
Primary objectives: To compare the disease free survival (DFS) in patients treated with the sequential epidoxorubicin, cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen to that in patients treated with the same…
- Trial name
- NCT00174707
- Testing
- epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile, epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile, epidoxorubicine, docetaxel, cyclophosphamide
- Where
- Italy
- Volunteers
- 998 people
- Sponsor
- Sanofi
Early Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC)…
- Trial name
- FeDeriCa (NCT03493854)
- Testing
- Cyclophosphamide, Doxorubicin, Docetaxel
- Where
- 107 sites in United States, Argentina and 17 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Breast Neoplasms, Neoplasms, Hormone-Dependent
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another…
- Trial name
- NCT00097344
- Testing
- Atamestane, Toremifene, Letrozole
- Where
- 104 sites in United States, Bulgaria and 3 more
- Volunteers
- 842 people
- Sponsor
- Intarcia Therapeutics
Malignant Neoplasm
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid…
- Trial name
- NCT06979596
- Testing
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate
- Where
- 60 sites in United States, Argentina and 11 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial to compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in patients with…
- Trial name
- NCT05110170
- Testing
- LY01005, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Luye Pharma Group Ltd.
Breast Cancer Subjects
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
The study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
- Trial name
- NCT06449027
- Testing
- T Leuprolide Injectable Emulsion, Leuprorelin Acetate Microspheres for Injection
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.